About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of care. Today in the journal Cancer Cell, scientists outline new findings about the origins of these lung cancer subtypes, paving the way for a new foundation to study this disease.... Read More
Improving Treatment Options for Patients With Lung Cancer
The Oliver Lab focuses on mechanisms of drug response and resistance in lung cancer with the goal of improving treatment options for patients with lung cancer.
Lung Cancer: Two Major Subtypes
Lung cancer is the leading cause of cancer-related death in the United States and is divided into two major subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). More than 80% of lung cancer patients have NSCLC, which are typically adenocarcinoma, squamous cell carcinoma or large cell carcinoma.
These patients are usually treated with combination chemotherapy regimens including a platinum-based compound such as cisplatin. However, only about 30% of tumors respond to therapy and the five-year survival rate is only 15%.
Approximately 20% of patients have small cell lung cancer (SCLC). SCLC is highly responsive to platinum-based chemotherapy with ~80% response rate. However, tumors almost always acquire resistance, and there are currently no targeted therapies approved for these patients. Drug resistance, both inherent and acquired, is a major problem preventing effective lung cancer treatment.
Personalizing Cancer Therapies
The Oliver Lab is interested in understanding mechanisms of therapeutic response and resistance in order to personalize cancer therapies based on the characteristics of a given tumor. Our approach is to integrate human genomics/sequencing data with mechanistic data gleaned from cell culture systems and sophisticated mouse models of lung cancer.
We use mouse models of lung cancer that closely resemble human lung cancer. Genes that are altered in human lung cancer are altered by genetic engineering in mice, or by lentiviral delivery of genes specifically to the mouse lung. We use bacterial Cre/LoxP systems and CRISPR/Cas9 systems to alter cancer genes in living mice. To monitor the therapeutic response of mouse lung tumors, we use state-of-the-art imaging technologies (such as micro-CT and bioluminescent imaging). We also use mouse and human cancer cell lines to probe the function of particular genes and signaling pathways.
Other techniques used in the lab include genomics, single-cell sequencing technologies, biochemistry, molecular and cellular biology, lentiviral technologies and high-throughput drug screening. We have numerous collaborators in the United States and internationally, and we work with pharmaceutical companies to test novel therapies in our mouse models.
News & Blog
Huntsman Cancer Institute Researchers Develop Potential New Treatment for MYC-driven Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death among men and women in Utah and the United States. Often, symptoms do not appear until the disease is advanced. Therefore, research studies toward better practices to prevent, find, and treat lung cancer are paramount. Research from scientists at Huntsman Cancer Institute yielded new insights into understanding potential new treatment options for MYC-driven tumors, a distinct subtype of small cell lung cancer.... Read More
The Lung Cancer Research Foundation (LCRF) announced the awardees of its 2018 Scientific Grant Program today during the Thirteenth Annual Lung Cancer Awareness Luncheon, held at The Pierre in New York City. Through this program, LCRF awarded $1.95 million in research grants to 13 investigators for innovative research focused on the prevention, diagnosis, and treatment of lung cancer. LCRF received a record-breaking 201 grant applications, representing 116 institutions and 21 countries in 2018. ... Read More
Research at Huntsman Cancer Institute at the University of Utah yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ultimately affect response to treatment. The results were published today in Immunity and featured on the print cover of the journal. ... Read More
Targeted therapy in cancer treatment is often called personalized or precision medicine, according to the National Institutes of Health. Targeted therapies are designed to be more effective and less harmful than other approaches because the drugs are specially designed to meet the individual characteristics of each patient.... Read More
Gurkan Mollaoglu, a graduate student in the Oliver Lab, received an F99 NCI Predoctoral to Postdoctoral Fellow Transition Award. This prestigious grant recognizes and supports outstanding graduate students who have demonstrated potential and interest in pursuing careers as independent cancer researchers. ... Read More